异基因造血干细胞移植后新发肾小球炎的六例临床分析
回顾性分析2008年1月至2016年12月河南省肿瘤医院478例异基因造血干细胞移植患者中6例(1.26%)新发肾小球炎的临床资料,中位发生时间为移植后447(272~1495)天,病理以膜性肾病为主(4例),5例采用低剂量环磷酰胺联合霉酚酸酯治疗,2例完全缓解、3例部分缓解。
要点
- 异基因造血干细胞移植后肾小球炎发生率为1.26%(6/478),中位发生时间447(272~1495)天。
- 肾脏病理以膜性肾病为主(4例),其余为微小病变型肾病1例、系膜增生性肾小球肾炎1例。
- 低剂量环磷酰胺联合霉酚酸酯治疗5例,2例完全缓解、3例部分缓解。
核心结论
- 异基因造血干细胞移植后肾小球炎的病理类型以膜性肾病为主,低剂量环磷酰胺联合霉酚酸酯可获得较好疗效。
研究设计与样本
- 回顾性分析2008年1月至2016年12月河南省肿瘤医院478例异基因造血干细胞移植后肾小球炎患者的临床资料,共6例。
主要发现
- 478例异基因造血干细胞移植患者中6例(1.26%)发生肾小球炎,男3例、女3例,中位年龄22(12~36)岁。
- 原发病为重型再生障碍性贫血2例、急性髓系白血病4例,移植前均无明确肾脏病病史,中位发生时间为移植后447(272~1495)天。
- 6例患者均有蛋白尿和不同程度水肿,4例肾功能异常,5例尿潜血阳性,3例高血压,2例高血脂。
- 5例患者曾发生急性移植物抗宿主病,4例发病时伴有慢性移植物抗宿主病。
- 肾脏病理为微小病变型肾病1例、膜性肾病4例、系膜增生性肾小球肾炎伴缺血性损伤1例;免疫组化IgG阳性4例、IgM阳性1例、C3阳性3例、C1q阳性1例。
关键数值与推荐
- 仅1例患者糖皮质激素治疗有效。
- 5例患者采用低剂量环磷酰胺联合霉酚酸酯治疗,2例完全缓解、3例部分缓解。
- 4例患者生存良好,2例患者死于肺感染。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the occurrence, clinical characteristics, diagnosis and treatment of glomerulitis after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: Analysis were carried out based on the clinical data of 6 patients with de novo glomerulitis following allo-HSCT hospitalized in Henan Tumor Hospital from January 2008 to December 2016, and the clinical manifestation, pathology, diagnosis, treatment and outcome were investigated. Results: The occurrence of glomerulitis was 1.26% (6/478). The median time was 447(272-1 495) d after allo-HSCT. Proteinuria and varying degrees of edema were present in all patients. Of the 6 patients, 4 patients with impaired renal function, 3 cases of hypertension, 5 cases of urine occult blood positive, 2 cases of hyperlipidemia. 5 patients underwent acute graft-versus-host disease (GVHD), 4 patients accompanied with chronic GVHD at diagnosis. Kidney pathology showed typical features of minimal change diseases in 1 patient, membranous nephropathy in 4 patients and mesangial proliferative glomerulonephritis in 1 case. Immunohistochemistry of glomerular lesions revealed that the immune complex deposition included IgG in 4 patients, C3 in 3 patients, IgM and C1q in 1 patient. Serum ANA was positive in 2 patients and serum IgG and IgM were in high level in 1 patient, respectively. Only 1 case was effective on glucocorticoid. 5 cases treated by low dose cyclophosphamide combined with mycophenolate mofetil (MMF), 2 cases achieved complete remission, and 3 cases were partial remission. Up to now, 2 cases died with lung infection, and 4 patients survived. Conclusion: The predominant pathological type of glomerulitis was membranous nephropathy. Low-dose cyclophosphamide combined with MMF was an effective treatment. 目的: 探讨异基因造血干细胞移植(allo-HSCT)后肾小球肾炎的发病、诊断及治疗情况。 方法: 回顾性分析2008年1月至2016年12月河南省肿瘤医院allo-HSCT后肾小球肾炎患者的临床资料。 结果: 478例allo-HSCT患者中6例(1.26%)发生肾小球肾炎,男3例,女3例,中位年龄22(12~36)岁;重型再生障碍性贫血(SAA)2例,急性髓系白血病(AML)4例,移植前均无明确的肾脏病病史,中位发生时间为移植后447(272~1 495)d。4例患者肾功能异常,5例尿潜血阳性,3例高血压,2例高血脂。5例患者曾发生急性GVHD,4例发病时伴有慢性GVHD。肾脏病理:微小病变型肾病1例,膜性肾病4例,系膜增生性肾小球肾炎伴缺血性损伤1例。肾脏免疫组化:IgG阳性4例,IgM阳性1例,C3阳性3例,C1q阳性1例。2例血清抗核抗体阳性,IgG和IgM升高各1例。仅1例患者糖皮质激素治疗有效。5例患者采用低剂量环磷酰胺联合霉酚酸酯治疗,2例完全有效,3例部分有效。4例患者生存良好,2例患者死于肺感染。 结论: allo-HSCT后肾小球肾炎的病理类型以膜性肾病为主,低剂量环磷酰胺联合霉酚酸酯可获得较好疗效。.
引用
- Zhou J, Zu YL, Gui RR, et al. [Clinical analysis of six cases with the de novo glomerulitis after allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30369188. doi:10.3760/cma.j.issn.0253-2727.2018.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。